Curium Announces Definitive Agreement to Merge with Lantheus

Curium US has agreed to acquire Lantheus Holdings for $102.50 per share in cash at closing, plus up to $12.00 per share in contingent value rights, valuing the transaction at up to $8.0 billion. The merger combines Curium's global theranostics platform and manufacturing capabilities with Lantheus' U.S. radiodiagnostics business, creating a combined entity serving oncology, neurology, and cardiology patients across more than 70 countries. The transaction is expected to close in the first half of 2027, subject to shareholder approval and regulatory clearances.